US · Healthcare · Biotechnology
EPS came in at -0.13 against a street estimate of -0.11 — a miss of 18.2%.
Analysts rate Taysha Gene Therapies Inc a strong buy (10 buy, 0 hold, 0 sell out of 10) with an average price target of $13.33.
| Fund | Stake |
|---|---|
| RA Capital Management, LLC | 7.25% |
| The Goldman Sachs Group Inc | 6.89% |
| venBio Select Advisor LLC | 6.68% |
| BlackRock Inc | 5.65% |
| Vestal Point Capital LP | 5.54% |
| Morgan Stanley - Brokerage Accounts | 5.53% |
| FMR Inc | 4.41% |
| RTW INVESTMENTS, LLC | 4.21% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 TAYSHA GENE THERAPIES, INC. – 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Cash Position: $455.4 million in cash and equivalents as of June 30, 2026 (u | 2026-08-11 |
| Results announced · Q3 2026 TAYSHA GENE THERAPIES Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash Position: $455.4 million as of June 30, 2026 (up from $319.8 million | 2026-08-11 |
| Material agreement · Q2 2026 TAYSHA GENE THERAPIES, INC. - 8-K SUMMARY HEADLINE NUMBERS • Public offering size: 32,500,001 shares of common stock at $6.00 per share, plus 833,33 | 2026-06-25 |
| Reg FD disclosure · Q2 2026 TAYSHA GENE THERAPIES, INC. - 8-K SUMMARY HEADLINE NUMBERS • Company: Taysha Gene Therapies, Inc. (Ticker: TSHA, Nasdaq) • Report Date: June 22, 202 | 2026-06-22 |
| Shareholder vote results · Q2 2026 TAYSHA GENE THERAPIES, INC. - 8-K SUMMARY HEADLINE NUMBERS • Annual meeting held June 1, 2026 with 243,857,812 shares present or represented by prox | 2026-06-02 |
| Quarterly report · Q1 2026 TAYSHA GENE THERAPIES, INC. – Q1 2026 10-Q SUMMARY --- HEADLINE NUMBERS • Cash position: $276.6 million as of March 31, 2026 (down from $319.8 mill | 2026-05-06 |
| Proxy statement · Q2 2026 TAYSHA GENE THERAPIES, INC. — 2026 PROXY SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect two directors to the Board's Class III sea | 2026-04-22 |
| Annual report FY2025 TAYSHA GENE THERAPIES, INC. – 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Company: Taysha Gene Therapies, Inc. (NASDAQ: TSHA) – clinical-st | 2026-03-19 |
Readable in the app.
| Announcement | Date |
|---|---|
| Regains full rights to TSHA-102 program in clinical evaluation Taysha Gene Therapies announced on October 16, 2025, that it has regained full rights to its TSHA-102 program, which is in clinical development for treating Rett Syndrome. This means the com | 2025-10-16 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Taysha Gene Therapies Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.